Clinical Trials Update provides you with latest news about clinical trials conducted by companies located in Medicon Valley and gives insight to progress in studies, results and possible indications. 

Lundbeck Further Strengthens Pipeline: Lu AA34893 into Clinical Phase II

19 February - H. Lundbeck A/S has decided to investigate Lu AA34893 for the treatment of bipolar disorder. The decision is based on positive pre-clinical results as well as positive conclusion of the phase I trials in healthy individuals. Bipolar disorder is a serious, life-long disorder, in which patients suffer from episodes of depression (lows) alternated with episodes of mania or hypomania (highs). The first patients in a 600-patient Phase II study have now been enrolled. 

- This study marks the first entry into bipolar disorder for Lundbeck and if successful, Lu AA34893 will provide a completely new approach to treat the needs of patients with bipolar disorder, said Senior Vice President Anders Gersel Pedersen, head of Development at Lundbeck.

Read more